{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:46:24Z","timestamp":1781264784581,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s10637-015-0283-x","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T00:13:05Z","timestamp":1440634385000},"page":"1144-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis"],"prefix":"10.1007","volume":"33","author":[{"given":"Tessa","family":"Tabouret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Dhooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Brezault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Dr\u00e9anic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Chaussade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Coriat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"key":"283_CR1","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jbspin.2006.01.025","volume":"73","author":"P Lafforgue","year":"2006","unstructured":"Lafforgue P (2006) Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine 73:500\u2013507","journal-title":"Joint Bone Spine"},{"key":"283_CR2","doi-asserted-by":"crossref","unstructured":"Mir O, Coriat R, Gregory T, Ropert S, Billemont B, et al. Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents. Invest New Drugs 29: 716\u2013718","DOI":"10.1007\/s10637-010-9406-6"},{"key":"283_CR3","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM, O\u2019Brien S, Sennino B et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610\u20132621","journal-title":"J Clin Invest"},{"key":"283_CR4","doi-asserted-by":"crossref","unstructured":"Arnold D, Andre T, Bennouna J, Sastre J, Osterlund PJ, et al (2012) Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 30, 2012 (suppl; abstr CRA3503) ASCO Annual Meeting","DOI":"10.1200\/jco.2012.30.18_suppl.cra3503"},{"key":"283_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2012","unstructured":"Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R et al (2012) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29\u201337","journal-title":"Lancet Oncol"},{"key":"283_CR6","doi-asserted-by":"crossref","unstructured":"Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"283_CR7","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an Oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506","journal-title":"J Clin Oncol"},{"key":"283_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"283_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","volume":"115","author":"AR Santos-Silva","year":"2013","unstructured":"Santos-Silva AR, Belizario Rosa GA, Castro Junior G, Dias RB, Prado Ribeiro AC et al (2013) Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 115:e32\u201336","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"283_CR10","first-page":"103","volume":"58C","author":"G Lescaille","year":"2013","unstructured":"Lescaille G, Coudert AE, Baaroun V, Ostertag A, Charpentier E et al (2013) Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. Bone 58C:103\u2013107","journal-title":"Bone"},{"key":"283_CR11","doi-asserted-by":"crossref","unstructured":"Koczywas M, Cristea MC Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 6: 1960\u20131961.","DOI":"10.1097\/JTO.0b013e31822e726f"},{"key":"283_CR12","doi-asserted-by":"crossref","unstructured":"Coriat R, Ropert S, Mir O, Billemont B, Chaussade S, et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 29: 1090\u20131093","DOI":"10.1007\/s10637-010-9458-7"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0283-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0283-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:47:41Z","timestamp":1678510061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0283-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0283-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,28]]},"assertion":[{"value":"13 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}